

Johnson & Johnson Innovative Medicine Pipeline

Key Events in 2023*

POTENTIAL APPROVALS US/EU

- ✓ US **AKEEGA (niraparib/abiraterone)**
- ✓ EU L1 Prostate cancer metastatic castration-resistant (MAGNITUDE)

- ✓ US **TALVEY (talquetamab)**
- ✓ EU Relapsed Refractory Multiple Myeloma

- ✓ US **ERLEADA (apalutamide)**
- ✓ EU Tablet Reduction

- TECVAYLI (teclistamab)
- ✓ EU Relapsed Refractory Multiple Myeloma Biweekly Dosing

PLANNED SUBMISSIONS US/EU

- ✓ US **AKEEGA (niraparib/abiraterone)**
- L1 Prostate cancer metastatic castration-resistant (MAGNITUDE)

- TALVEY (talquetamab)**
- ✓ EU Relapsed Refractory Multiple Myeloma

- ✓ US **BALVERSA (erdafitinib)**
- ✓ EU Urothelial Cancer (THOR)

- ✓ US **CARVYKTI (ciltacabtagene autoleucel)**
- ✓ EU Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4)

- ✓ US **EDURANT (rilpivirine)**
- ✓ EU HIV pediatric 2-12 year old

- OPSUMIT (macitentan)**
- ✓ EU Pediatric pulmonary arterial hypertension (TOMORROW)

- ✓ US **OPSYNVI (macitentan/tadalafil STCT)**
- ✓ EU Pulmonary arterial hypertension

- ✓ US **RYBREVANT (amivantamab)**
- ✓ EU Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

- ✓ US **RYBREVANT / lazertinib**
- ✓ EU Non Small Cell Lung Cancer 2L (MARIPOSA-2)

- ✓ US **RYBREVANT / lazertinib**
- ✓ EU Non Small Cell Lung Cancer (MARIPOSA)

POTENTIAL CLINICAL DATA

Phase III

- ✓ **CARVYKTI (ciltacabtagene autoleucel)**
- Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4)

- ✓ **BALVERSA (erdafitinib)**
- Urothelial Cancer (THOR)

- ✓ **RYBREVANT (amivantamab)**
- Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

- ✓ **IMBRUVICA (ibrutinib)**
- Relapsed Refractory patients with Mantle Cell Lymphoma in combination with venetoclax (SYMPATICO)

- ✓ **RYBREVANT / lazertinib**
- Non Small Cell Lung Cancer 2L (MARIPOSA-2)

- ✓ **RYBREVANT / lazertinib**
- Non Small Cell Lung Cancer (MARIPOSA)

- ✓ **OPSYNVI (macitentan/tadalafil STCT)**
- Pulmonary arterial hypertension (A DUE)

- ✓ **SPRAVATO (esketamine)**
- Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

- TREMFYA (guselkumab)**
- Crohn's Disease (GALAXI)

- ✓ **TREMFYA (guselkumab)**
- Ulcerative Colitis Monotherapy

- ✓ **DARZALEX (daratumumab)**
- Frontline multiple myeloma transplant eligible (PERSEUS)

Phase I/II

- ✓ **TAR-200 (RIS/gemcitabine plus cetrelimab)**
- Non muscle invasive bladder cancer (SR-1 Early Data)

- ✓ **TAR-210 (RIS/erdafitinib)**
- Non Muscle Invasive Bladder Cancer (Early Data)

- ✓ **TAR-200 (RIS/gemcitabine plus cetrelimab)**
- Non Muscle Invasive Bladder Cancer (SunRISe-1 Update)

- ✓ **BALVERSA (erdafitinib)**
- Tumor Agnostic (RAGNAR)

- RYBREVANT (amivantamab)**
- Solid Tumors (GIC2001)

- ✓ **JNJ-2113**
- Psoriasis

- ✓ **nipocalimab**
- Rheumatoid Arthritis

- ✓ **nipocalimab**
- Hemolytic disease of the fetus and newborn

- ✓ **JNJ-5322 (BCMA/BPRC5D/CD3)**
- Hematological Malignancies (Ph I Data)



✓ = Achieved

*This information is as of January 23, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.